

DAFTAR PUSTAKA

- Al Quran dan Terjemahnya. 2009. Kementerian Agama Republik Indonesia. Jakarta: Halim.
- Aidh bin Abdullah. 2005. Dont be Sad, La tahzan, Cara Hidup Positif Tanpa Pernah Sedih dan Frustrasi. Maghfirah Pustaka. Jakarta.
- Archer Melisa dan Oderda Gary. 2013. Teriflunomide (Aubagio) Drug Review. University of Utah College of Pharmacy, pp 3-9.
- Cohen JA, Coles AJ, Arnold DL, et al. 2012. Alemtuzumab Versus Interferon Beta 1a as First-line Treatment for Patients with Relapsing_remitting Multiple Sclerosis: A Randomised Controlled Phase 3 Trial. *Lancet*, 380, pp 1819–1828.
- Coles AJ, Twyman CL, Arnold DL, et al. 2012. Alemtuzumab for Patients with Relapsing Multiple Sclerosis After Disease-modifying Therapy: A Randomised Controlled Phase 3 Trial. *Lancet* 2012, 380, pp 1829–1839.
- Confavreux Christian, O'Connor Paul, Comi Giancarlo, et al. 2014. Oral Teriflunomide for Patients with Relapsing Multiple Sclerosis (TOWER): A Randomised, Double-blind, Placebo Controlled, Phase 3 Trial. *Lancet Neurology*, 13, pp 247-256
- D He, Z Hu, S Dong, et al. 2012. Teriflunomide for Multiple Sclerosis (Review). The Cochrane Collaboration. Published by JohnWiley & Sons, Ltd. Issue 12.
- Dhib-Jalbut S dan Marks S. 2010. Interferon-b Mechanisms of Action in Multiple Sclerosis. *Neurology*, 74(Suppl.1), pp 17-24.
- Food Drug Administration. 2012. Teriflunomide. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202992s0001bl.pdf Diunduh tanggal 6 Maret 2016 jam 13.00 WIB.
- Freedman Mark S. 2013. Teriflunomide in Relapsing Multiple Sclerosis: Therapeutic Utility. Department of Medicine (Neurology) University of Ottawa, 4(5), pp 192-205
- H Noda, Takeuchi H, Mizuno T, Suzumura A. et al. 2013. Fingolimod Phosphate Promotes the Neuroprotective Effects of microglia. *J Neuroimmunol*, 256, pp 13-18.

- Genzyme Corporation (2012) *Aubagio Prescribing Information*. Cambridge, MA: Genzyme Corporation
- Greenberg David A, Aminoff Michael J, Simon Roger P. 2012. *Clinical Neurology*. International edition Mc Graw Hill Lange.
- Ginsberg Lionel. 2007. *Neurologi*. Penerbit Erlangga, pp 143-150.
- Gold R. dan Wolinsky J. 2011. Pathophysiology of Multiple Sclerosis and the Place of Teriflunomide. *Acta Neurol Scand*, 124, pp 75–84.
- Kappos L, Radue EW, O'Connor P, et al. 2010. A Placebo Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. *N Engl J Med*, 362, 387401.
- Limsakun T dan Menguy-Vacheron F. 2010. Pharmacokinetics of Oral Teriflunomide, a Novel Oral Disease-modifying Agent Under Investigation for the Treatment of Multiple Sclerosis. In: *Proceedings of the 62nd Annual Meeting of the American Academy of Neurology*.
- Linker dan Gold. 2013. Dimethyl Fumarate for Treatment of Multiple Sclerosis: mechanism of action, effectiveness, and side effects. *Curr Neurol Neurosci Rep*, 13: 394.
- Loma, I. dan Heyman, R. (2011) Multiple sclerosis: Pathogenesis and Treatment. *Curr Neuropharmacol* 9, pp 409–416.
- Luzzio, C. 2015. Multiple Sclerosis. www.emedicine.com. Diunduh tanggal 5 Maret 2016 jam 20.00 WIB.
- Marriot JJ, Miyasaki, Gronseth, O'Connor. 2010. Evidence Report: The efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*, 74(18), pp 1463-1470.
- Miller A, Turpault S, dan Menguy-Vacheron F. 2012. Rapid Elimination Procedure of Teriflunomide with Cholestyramine or Activated Charcoal. In *Fourth Cooperative Meeting of CMSC and ACTRIMS*, 30 May–2 June 2012, San Diego, CA, USA, P10.
- Mumenthaler Mark, Mattle Heirich, Taub Ethan. 2006. *Fundamental of Neurology*. Thieme.

- O'Connor Paul, Wolinsky Jerry S, Confavreux Christian, et al. 2012. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. *The New England Journal of Medicine*, 365, 1293-1303
- Oh dan O'conor. 2014. Teriflunomide in the Treatment of Multiple Sclerosis: Current Evidence and Future Prospects. *Ther Adv Neurol Disord*, 7(5) 239–252. Reprints and permissions: <http://www.sagepub.co.uk/>
- Polman CH, O'Connor PW, Havrdova E, et al. 2006. A randomized, Placebo-controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. *N Engl J Med*, 354, pp 899–910.
- Racke Michael dan Lovett-Racke Amy. 2011. Glatiramer Acetate Treatment of Multiple Sclerosis: An Immunological Perspective. *The Journal of Immunology*, 186, pp 1887-1890.
- Rohkamm Reinhard. 2004. *Color Atlas of Neurology*. Thieme.
- Taslim Abdullah. 2010. Sikap Seorang Muslim dalam Menghadapi Musibah. <https://muslim.or.id/5026-sikap-seorang-muslim-dalam-menghadapi-musibah.html>. Diakses pada tanggal 5 maret 2016. Jam 07.00.
- Torkildsen, Myhr, et al. 2015. Disease-modifying treatments for multiple sclerosis – a review of approved medications. *European Journal of Neurology* 2015, 23 (Suppl. 1): 18–27
- Wang L, Van Horn R, Turpault S, dan Zeng Z. 2011. Metabolism comparison between leflunomide and teriflunomide in humans. *Eur J Neurol* 18(Suppl. 2), 268.
- Warnke Clements, Kiesier Bernds C, Stuve olaf. 2013. Teriflunomide for the treatment of multiple sclerosis. *Clinical Neurology and Neurosurgery*, 115S, pp S90– S94. Journal homepage: www.elsevier.com/locate/clinuro
- Wibowo, A. 2012. Maqoshid Asy Syariah: The Ultimate Objective of Syariah. Diunduh dari: www.staff.uny.ac.id. Diakses tanggal 5 Maret 2016. Jam 07.00
- Wu GF dan Alvarez E. The immuno-pathophysiology of multiple sclerosis. *Neurol Clin*. 2011 May ; 29(2), pp 257-78.
- Zuhroni *et al*. 2003. *Islam Untuk Ilmu Kesehatan dan Kedokteran 2 (Fiqh Kontemporer)*. Departemen Agama RI Direktorat Jendral Kelembagaan Agama Islam. Jakarta.

Zuhroni. 2010. Dasar dan Sumber Syariat Islam. Jakarta. Bagian Agama Islam
Universitas Yarsi